{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T14:29:40Z","timestamp":1790260180409,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,3,13]],"date-time":"2017-03-13T00:00:00Z","timestamp":1489363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,3,13]],"date-time":"2017-03-13T00:00:00Z","timestamp":1489363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004388","name":"Oncolytics Biotech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004388","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1007\/s00280-017-3260-6","type":"journal-article","created":{"date-parts":[[2017,3,13]],"date-time":"2017-03-13T16:10:14Z","timestamp":1489421414000},"page":"697-703","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":87,"title":["A phase II study of REOLYSIN\u00ae (pelareorep) in combination with carboplatin and paclitaxel for patients with advanced malignant melanoma"],"prefix":"10.1007","volume":"79","author":[{"given":"Devalingam","family":"Mahalingam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Fountzilas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Moseley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Noronha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hue","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romit","family":"Chakrabarty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Selvaggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Coffey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Sarantopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,3,13]]},"reference":[{"issue":"1","key":"3260_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21332","volume":"66","author":"RL Siegel","year":"2016","unstructured":"Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66(1):7\u201330. doi:10.3322\/caac.21332","journal-title":"CA Cancer J Clin"},{"issue":"12","key":"3260_CR2","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/S1470-2045(03)01280-4","volume":"4","author":"TK Eigentler","year":"2003","unstructured":"Eigentler TK, Caroli UM, Radny P, Garbe C (2003) Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol 4(12):748\u2013759","journal-title":"Lancet Oncol"},{"key":"3260_CR3","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ejca.2015.09.013","volume":"53","author":"S Ugurel","year":"2016","unstructured":"Ugurel S, R\u00f6hmel J, Ascierto PA, Flaherty KT, Grob JJ, Hauschild A, Larkin J, Long GV, Lorigan P, McArthur GA, Ribas A, Robert C, Schadendorf D, Garbe C (2016) Survival of patients with advanced metastatic melanoma: the impact of novel therapies. Eur J Cancer 53:125\u2013134. doi:10.1016\/j.ejca.2015.09.013","journal-title":"Eur J Cancer"},{"issue":"5392","key":"3260_CR4","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1126\/science.282.5392.1332","volume":"282","author":"MC Coffey","year":"1998","unstructured":"Coffey MC, Strong JE, Forsyth PA, Lee PW (1998) Reovirus therapy of tumors with activated Ras pathway. Science 282(5392):1332\u20131334","journal-title":"Science"},{"issue":"12","key":"3260_CR5","doi-asserted-by":"publisher","first-page":"3351","DOI":"10.1093\/emboj\/17.12.3351","volume":"17","author":"JE Strong","year":"1998","unstructured":"Strong JE, Coffey MC, Tang D, Sabinin P, Lee PW (1998) The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. Embo J 17 (12):3351\u20133362","journal-title":"Embo J"},{"issue":"18","key":"3260_CR6","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1038\/gt.2008.58","volume":"15","author":"F Errington","year":"2008","unstructured":"Errington F, White CL, Twigger KR, Rose A, Scott K, Steele L, Ilett LJ, Prestwich R, Pandha HS, Coffey M, Selby P, Vile R, Harrington KJ, Melcher AA (2008) Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma. Gene Ther 15(18):1257\u20131270","journal-title":"Gene Ther"},{"issue":"3","key":"3260_CR7","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1007\/s10637-012-9865-z","volume":"31","author":"DG Morris","year":"2013","unstructured":"Morris DG, Feng X, DiFrancesco LM, Fonseca K, Forsyth PA, Paterson AH, Coffey MC, Thompson B (2013) REO-001: a phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin\u00ae) in patients with advanced solid tumors. Invest New Drugs 31(3):696\u2013706. doi:10.1007\/s10637-012-9865-z","journal-title":"Invest New Drugs"},{"issue":"10","key":"3260_CR8","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1038\/mt.2012.146","volume":"20","author":"E Galanis","year":"2012","unstructured":"Galanis E, Markovic SN, Suman VJ, Nuovo GJ, Vile RG, Kottke TJ, Nevala WK, Thompson MA, Lewis JE, Rumilla KM, Roulstone V, Harrington K, Linette GP, Maples WJ, Coffey M, Zwiebel J, Kendra K (2012) Phase II trial of intravenous administration of reolysin[reg] (reovirus serotype-3-dearing strain) in patients with metastatic melanoma. Mol Ther 20(10):1998\u20132003","journal-title":"Mol Ther"},{"issue":"22","key":"3260_CR9","doi-asserted-by":"publisher","first-page":"7358","DOI":"10.1158\/1078-0432.ccr-08-0831","volume":"14","author":"RJ Prestwich","year":"2008","unstructured":"Prestwich RJ, Errington F, Ilett EJ, Morgan RSM, Scott KJ, Kottke T, Thompson J, Morrison EE, Harrington KJ, Pandha HS, Selby PJ, Vile RG, Melcher AA (2008) Tumor infection by oncolytic reovirus primes adaptive antitumor immunity. Am Assoc Cancer Res 14(22):7358\u20137366. doi:10.1158\/1078-0432.ccr-08-0831","journal-title":"Am Assoc Cancer Res"},{"issue":"13","key":"3260_CR10","doi-asserted-by":"publisher","first-page":"4374","DOI":"10.1158\/1078-0432.ccr-09-0334","volume":"15","author":"RJ Prestwich","year":"2009","unstructured":"Prestwich RJ, Ilett EJ, Errington F, Diaz RM, Steele LP, Kottke T, Thompson J, Galivo F, Harrington KJ, Pandha HS, Selby PJ, Vile RG, Melcher AA (2009) Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication. Am Assoc Cancer Res 15(13):4374\u20134381. doi:10.1158\/1078-0432.ccr-09-0334","journal-title":"Am Assoc Cancer Res"},{"key":"3260_CR11","doi-asserted-by":"crossref","unstructured":"White CL, Twigger KR, Vidal L, De Bono JS, Coffey M, Heinemann L, Morgan R, Merrick A, Errington F, Vile RG, Melcher AA, Pandha HS, Harrington KJ (2008) Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial. Gene Ther 15(12):911\u2013920. http:\/\/www.nature.com\/gt\/journal\/v15\/n12\/suppinfo\/gt200821s1.html","DOI":"10.1038\/gt.2008.21"},{"issue":"1","key":"3260_CR12","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1158\/1078-0432.ccr-07-1510","volume":"14","author":"J Qiao","year":"2008","unstructured":"Qiao J, Wang H, Kottke T, White C, Twigger K, Diaz RM, Thompson J, Selby P, de Bono J, Melcher A, Pandha H, Coffey M, Vile R, Harrington K (2008) Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus. Am Assoc Cancer Res 14(1):259\u2013269. doi:10.1158\/1078-0432.ccr-07-1510","journal-title":"Am Assoc Cancer Res"},{"issue":"2","key":"3260_CR13","first-page":"348","volume":"63","author":"K Hirasawa","year":"2003","unstructured":"Hirasawa K, Nishikawa SG, Norman KL, Coffey MC, Thompson BG, Yoon C-S, Waisman DM, Lee PWK (2003) Systemic reovirus therapy of metastatic cancer in immune-competent mice. Cancer Res 63(2):348\u2013353","journal-title":"Cancer Res"},{"issue":"2","key":"3260_CR14","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1002\/cncr.21611","volume":"106","author":"RD Rao","year":"2006","unstructured":"Rao RD, Holtan SG, Ingle JN, Croghan GA, Kottschade LA, Creagan ET, Kaur JS, Pitot HC, Markovic SN (2006) Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma. Cancer 106(2):375\u2013382. doi:10.1002\/cncr.21611","journal-title":"Cancer"},{"issue":"5","key":"3260_CR15","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1097\/00008390-200310000-00012","volume":"13","author":"C Zimpfer-Rechner","year":"2003","unstructured":"Zimpfer-Rechner C, Hofmann U, Figl R, Becker JC, Trefzer U, Keller I, Hauschild A, Schadendorf D (2003) Randomized phase II study of weekly paclitaxel versus paclitaxel and carboplatin as second-line therapy in disseminated melanoma: a multicentre trial of the Dermatologic Co-operative Oncology Group (DeCOG). Melanoma Res 13(5):531\u2013536. doi:10.1097\/01.cmr.0000056274.56735.c6","journal-title":"Melanoma Res"},{"issue":"3","key":"3260_CR16","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1097\/00000421-200206000-00016","volume":"25","author":"FS Hodi","year":"2002","unstructured":"Hodi FS, Soiffer RJ, Clark J, Finkelstein DM, Haluska FG (2002) Phase II study of paclitaxel and carboplatin for malignant melanoma. Am J Clin Oncol 25(3):283\u2013286","journal-title":"Am J Clin Oncol"},{"issue":"7","key":"3260_CR17","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1158\/1078-0432.ccr-11-2181","volume":"18","author":"EM Karapanagiotou","year":"2012","unstructured":"Karapanagiotou EM, Roulstone V, Twigger K, Ball M, Tanay M, Nutting C, Newbold K, Gore ME, Larkin J, Syrigos KN, Coffey M, Thompson B, Mettinger K, Vile RG, Pandha HS, Hall GD, Melcher AA, Chester J, Harrington KJ (2012) Phase I\/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies. Am Assoc Cancer Res 18(7):2080\u20132089. doi:10.1158\/1078-0432.ccr-11-2181","journal-title":"Am Assoc Cancer Res"},{"issue":"19","key":"3260_CR18","doi-asserted-by":"publisher","first-page":"6158","DOI":"10.1158\/1078-0432.ccr-09-0796","volume":"15","author":"HS Pandha","year":"2009","unstructured":"Pandha HS, Heinemann L, Simpson GR, Melcher A, Prestwich R, Errington F, Coffey M, Harrington KJ, Morgan R (2009) Synergistic effects of oncolytic reovirus and cisplatin chemotherapy in murine malignant melanoma. Am Assoc Cancer Res 15(19):6158\u20136166. doi:10.1158\/1078-0432.ccr-09-0796","journal-title":"Am Assoc Cancer Res"},{"key":"3260_CR19","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/1476-4598-8-47","volume":"8","author":"S Sei","year":"2009","unstructured":"Sei S, Mussio JK, Yang Q-e, Nagashima K, Parchment RE, Coffey MC, Shoemaker RH, Tomaszewski JE (2009) Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells. Mol Cancer 8:47\u201347. doi:10.1186\/1476-4598-8-47","journal-title":"Mol Cancer"},{"issue":"(11 Supplement)","key":"3260_CR20","doi-asserted-by":"publisher","first-page":"C70C70","DOI":"10.1158\/1535-7163.targ-13-c70","volume":"12","author":"AC Mita","year":"2013","unstructured":"Mita AC, Argiris A, Coffey M, Gill G, Mita M (2013) Abstract C70: A phase 2 study of intravenous administration of REOLYSIN\u00ae (reovirus type 3 dearing) in combination with paclitaxel (P) and carboplatin (C) in patients with squamous cell carcinoma of the lung. Am Assoc Cancer Res 12(11 Supplement):C70-C70. doi:10.1158\/1535-7163.targ-13-c70","journal-title":"Am Assoc Cancer Res"},{"issue":"6","key":"3260_CR21","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1002\/cncr.29856","volume":"122","author":"MA Villalona-Calero","year":"2016","unstructured":"Villalona-Calero MA, Lam E, Otterson GA, Zhao WQ, Timmons M, Subramaniam D, Hade EM, Gill GM, Coffey M, Selvaggi G, Bertino E, Chao B, Knopp MV (2016) Oncolytic reovirus in combination with chemotherapy in metastatic or recurrent non-small cell lung cancer patients with KRAS-activated tumors. Cancer 122(6):875\u2013883. doi:10.1002\/cncr.29856","journal-title":"Cancer"},{"issue":"25","key":"3260_CR22","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","volume":"33","author":"RHI Andtbacka","year":"2015","unstructured":"Andtbacka RHI, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, Delman KA, Spitler LE, Puzanov I, Agarwala SS, Milhem M, Cranmer L, Curti B, Lewis K, Ross M, Guthrie T, Linette GP, Daniels GA, Harrington K, Middleton MR, Miller WH, Zager JS, Ye YN, Yao B, Li A, Doleman S, VanderWalde A, Gansert J, Coffin RS (2015) Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol 33(25):2780\u20132798. doi:10.1200\/jco.2014.58.3377","journal-title":"J Clin Oncol"},{"issue":"(15_suppl)","key":"3260_CR23","first-page":"9029","volume":"32","author":"I Puzanov","year":"2014","unstructured":"Puzanov I, Milhem MM, Andtbacka RHI, Minor DR, Hamid O, Li A, Chastain M, Gorski K, Anderson A, Vanderwalde AM, Chou J, Kaufman H (2014) Primary analysis of a phase 1b multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma. ASCO Meeting Abstr 32(15_suppl):9029","journal-title":"ASCO Meeting Abstr"},{"issue":"(15_suppl)","key":"3260_CR24","first-page":"9063","volume":"33","author":"I Puzanov","year":"2015","unstructured":"Puzanov I, Milhem MM, Andtbacka RHI, Minor DR, Hamid O, Li A, Chou J, Kaufman H (2015) Survival, safety, and response patterns in a phase 1b multicenter trial of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma. ASCO Meeting Abstr 33(15_suppl):9063","journal-title":"ASCO Meeting Abstr"},{"issue":"(15_suppl)","key":"3260_CR25","first-page":"9568","volume":"34","author":"GV Long","year":"2016","unstructured":"Long GV, Dummer R, Ribas A, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O, Olszanski AJ, Malvehy J, Cebon JS, Fernandez E, Kirkwood JM, Gajewski T, Gause CK, Chen L, Gorski K, Anderson A, Kaufman DR, Chou J, Hodi FS (2016) Efficacy analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma. ASCO Meeting Abstr 34 (15_suppl):9568","journal-title":"ASCO Meeting Abstr"},{"issue":"5","key":"3260_CR26","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1038\/mt.2015.15","volume":"23","author":"V Roulstone","year":"2015","unstructured":"Roulstone V, Pedersen M, Kyula J, Mansfield D, Khan AA, McEntee G, Wilkinson M, Karapanagiotou E, Coffey M, Marais R, Jebar A, Errington-Mais F, Melcher A, Vile R, Pandha H, McLaughlin M, Harrington KJ (2015) BRAF- and MEK-targeted small molecule inhibitors exert enhanced antimelanoma effects in combination with oncolytic reovirus through ER stress. Mol Ther 23(5):931\u2013942. doi:10.1038\/mt.2015.15","journal-title":"Mol Ther"},{"issue":"1","key":"3260_CR27","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/mt.2015.156","volume":"24","author":"K Rajani","year":"2016","unstructured":"Rajani K, Parrish C, Kottke T, Thompson J, Zaidi S, Ilett L, Shim KG, Diaz R-M, Pandha H, Harrington K, Coffey M, Melcher A, Vile R (2016) combination therapy with reovirus and anti-PD-1 blockade controls tumor growth through innate and adaptive immune responses. Mol Ther 24(1):166\u2013174. doi:10.1038\/mt.2015.156","journal-title":"Mol Ther"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-017-3260-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-017-3260-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-017-3260-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T01:43:24Z","timestamp":1659059004000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-017-3260-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,13]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["3260"],"URL":"https:\/\/doi.org\/10.1007\/s00280-017-3260-6","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,13]]},"assertion":[{"value":"18 November 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"This study was funded by Oncolytics Inc (study sponsor).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Devalingam Mahalingam declares that he has no conflict of interest. Christos Fountzilas declares that he has no conflict of interest. Jennifer Moseley declares that she has no conflict of interest. John Sarantopoulos declares that he has no conflict of interest. Nicole Noronha, Hue Tran, Romit Chakrabarty, Matt Coffey, and Brad Thompson are employed by Oncolytics Biotech Inc., with stock options and\/or stock. Giovanni Selvaggi was employed with Oncolytics Biotech Inc. during a portion of this study and manuscript preparation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}